Supplementary Figure 2: The pharmacokinetics and pharmacodistribution of rATRAM-GRA8-M/AS. (A) The
pharmacokinetics and pharmacodistribution against rATRAM-GRA8-M/AS in tumor-bearing mice. HCT116 cells were subcutaneously injected into the flanks of BALB/c mice, as described in the Methods section. The mice were administrated by i.p. at one or two times and sacrificed on day 5. His expression was assessed by immunoblotting (IB) in various organs from mice. Whole-cell lysates were used for the IB with αActin. The data are representative of four independent experiments with similar results. (B) Schematic of the xenograft model treated with or rGRA8 WT (upper). HCT116 cells were subcutaneously injected into the flanks of nude mice. The length and width of the tumors were measured using calipers, and the tumor volume was calculated every third day for 30 days. Individual tumor volumes from each mouse from each group were averaged and plotted against the number days postinoculation. Statistical significance was determined by two-way analysis of variance (ANOVA) with Tukey's posttest; * P < 0.05, ***
